MA45168A - Peptidomimétique en épingle à cheveux bêta ayant une activité inhibitrice à l'encontre de l'élastase, et ses formes posologiques en aérosol - Google Patents

Peptidomimétique en épingle à cheveux bêta ayant une activité inhibitrice à l'encontre de l'élastase, et ses formes posologiques en aérosol

Info

Publication number
MA45168A
MA45168A MA045168A MA45168A MA45168A MA 45168 A MA45168 A MA 45168A MA 045168 A MA045168 A MA 045168A MA 45168 A MA45168 A MA 45168A MA 45168 A MA45168 A MA 45168A
Authority
MA
Morocco
Prior art keywords
inhibitoring
peptidomimetic
elastase
activity
dosage forms
Prior art date
Application number
MA045168A
Other languages
English (en)
Inventor
Philip Barth
Piet Bruijnzeel
Eric Chevalier
Manfred Keller
Christian Ludin
Johann Zimmermann
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of MA45168A publication Critical patent/MA45168A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
MA045168A 2016-05-31 2017-05-31 Peptidomimétique en épingle à cheveux bêta ayant une activité inhibitrice à l'encontre de l'élastase, et ses formes posologiques en aérosol MA45168A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16020210 2016-05-31

Publications (1)

Publication Number Publication Date
MA45168A true MA45168A (fr) 2019-04-10

Family

ID=56108445

Family Applications (2)

Application Number Title Priority Date Filing Date
MA045168A MA45168A (fr) 2016-05-31 2017-05-31 Peptidomimétique en épingle à cheveux bêta ayant une activité inhibitrice à l'encontre de l'élastase, et ses formes posologiques en aérosol
MA045167A MA45167A (fr) 2016-05-31 2017-05-31 Peptidomimétique en épingle à cheveux bêta présentant une activité d'inhibition de l'élastase et formes pharmaceutiques aérosols correspondantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA045167A MA45167A (fr) 2016-05-31 2017-05-31 Peptidomimétique en épingle à cheveux bêta présentant une activité d'inhibition de l'élastase et formes pharmaceutiques aérosols correspondantes

Country Status (27)

Country Link
US (3) US11235023B2 (fr)
EP (2) EP3463281B1 (fr)
JP (4) JP7286319B6 (fr)
KR (2) KR102480800B1 (fr)
CN (3) CN109195580A (fr)
AU (2) AU2017273508B2 (fr)
BR (2) BR112018074532B1 (fr)
CA (2) CA3024522C (fr)
CL (2) CL2018003391A1 (fr)
DK (2) DK3463280T3 (fr)
EA (2) EA039603B1 (fr)
ES (2) ES2927948T3 (fr)
HR (2) HRP20221185T1 (fr)
HU (2) HUE060119T2 (fr)
IL (2) IL263112B2 (fr)
LT (2) LT3463281T (fr)
MA (2) MA45168A (fr)
MX (2) MX393629B (fr)
PH (2) PH12018502522A1 (fr)
PL (2) PL3463281T3 (fr)
PT (2) PT3463281T (fr)
RS (2) RS63622B1 (fr)
SG (3) SG11201810137UA (fr)
SM (2) SMT202200405T1 (fr)
UA (2) UA125899C2 (fr)
WO (2) WO2017207117A1 (fr)
ZA (2) ZA201807772B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX393629B (es) * 2016-05-31 2025-03-24 Polyphor Ag Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma.
JP2022544834A (ja) * 2019-08-23 2022-10-21 ピーエイチ・ファーマ・カンパニー・リミテッド 肺疾患における好中球エラスターゼ阻害剤の使用
BR112022014861A2 (pt) * 2020-01-30 2022-09-20 Vertex Pharma Métodos de tratamento para deficiência de alfa-1 antittripsina
WO2021203014A1 (fr) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Dérivés de pyrano [4,3-b] indole en tant que modulateurs d'alpha-1-antitrypsine pour traiter une déficience en alpha-1-antitrypsine (aatd)
EP4126863A1 (fr) 2020-04-03 2023-02-08 Vertex Pharmaceuticals Incorporated Dérivés de 1h-pyrazolo [4,3-g] isoquinoléine et de 1h-pyrazolo [4,3-g] quinoléine en tant que modulateurs d'alpha-1-antitrypsine pour traiter une déficience en alpha-1-antitrypsine (aatd)
JP2023549971A (ja) * 2020-11-23 2023-11-29 スペクシス アーゲー ベータヘアピン型ペプチド模倣物の組成物及びそのエアロゾル投与形態
CN116421704A (zh) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019694A1 (fr) 1996-11-01 1998-05-14 Xoma Corporation Emplois therapeutiques des produits de la proteine bpi chez des patients atteints de mucoviscidose
US20060188555A1 (en) * 2005-01-21 2006-08-24 Micheal Cormier Therapeutic peptide formulations with improved stability
CA2598360C (fr) * 2005-02-17 2016-12-20 Universitat Zurich Peptidomimetiques en epingle a cheveux beta fixes sur matrice, ayant une activite inhibitrice des proteases
EP1712220A1 (fr) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Composition d'aérosol pharmaceutique
PT1981572E (pt) * 2006-02-09 2013-02-26 Pari Pharma Gmbh Distribuição pulmonar de inibidor de alfa-i proteinase
JP2009526003A (ja) * 2006-02-10 2009-07-16 パーリ・ファルマ・ゲーエムベーハー 吸入療法用噴霧状抗生物質
WO2008025560A1 (fr) 2006-09-01 2008-03-06 Pari Pharma Gmbh Procédés servant à masquer le goût de compositions nébulisées pour thérapie par inhalation nasale et pulmonaire
EP1927373B1 (fr) * 2006-11-30 2012-08-22 PARI Pharma GmbH Nebuliseur d'inhalation
PL2567691T3 (pl) * 2011-09-12 2015-05-29 Meiji Seika Pharma Co Ltd Kompozycje wodne obejmujące arbekacynę
WO2015096672A1 (fr) 2013-12-23 2015-07-02 石家庄铁道大学 Dispositif de détection
JP6431486B2 (ja) 2013-12-26 2018-11-28 株式会社カネカ 太陽電池のｉ‐ｖ測定方法、太陽電池のｉ‐ｖ測定装置、太陽電池の製造方法、太陽電池モジュールの製造方法、および太陽電池モジュール
NZ722025A (en) * 2013-12-27 2019-06-28 Polyphor Ag Beta-hairpin peptidomimetics as selective elastase inhibitors
EA034910B1 (ru) * 2013-12-27 2020-04-06 Полифор Аг Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы
MX393629B (es) * 2016-05-31 2025-03-24 Polyphor Ag Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma.

Also Published As

Publication number Publication date
US20200230202A1 (en) 2020-07-23
WO2017207117A1 (fr) 2017-12-07
HUE060393T2 (hu) 2023-02-28
KR102480800B1 (ko) 2022-12-22
UA125899C2 (uk) 2022-07-06
JP7544466B2 (ja) 2024-09-03
DK3463281T3 (da) 2022-09-26
JP2023017793A (ja) 2023-02-07
LT3463281T (lt) 2022-09-26
MX393629B (es) 2025-03-24
IL263114B2 (en) 2023-12-01
JP2022078013A (ja) 2022-05-24
EP3463280B1 (fr) 2022-07-06
DK3463280T3 (da) 2022-09-26
PH12018502522A1 (en) 2019-10-21
US20220023379A1 (en) 2022-01-27
AU2017273507B2 (en) 2022-03-17
PL3463281T3 (pl) 2022-11-07
EA201892819A1 (ru) 2019-05-31
MX2018014425A (es) 2019-03-28
BR112018074551B1 (pt) 2022-02-08
EA201892818A1 (ru) 2019-05-31
EP3463281B1 (fr) 2022-07-06
SMT202200405T1 (it) 2022-11-18
LT3463280T (lt) 2022-09-26
PL3463280T3 (pl) 2022-11-07
PH12018502521A1 (en) 2019-10-21
UA125900C2 (uk) 2022-07-06
CL2018003390A1 (es) 2019-05-03
BR112018074532A2 (pt) 2019-03-19
EP3463280A1 (fr) 2019-04-10
IL263114B1 (en) 2023-08-01
SG11201810138XA (en) 2018-12-28
AU2017273508B2 (en) 2022-07-28
JP7286319B6 (ja) 2023-06-16
IL263112B1 (en) 2023-06-01
PT3463281T (pt) 2022-10-07
US11235024B2 (en) 2022-02-01
CA3024521C (fr) 2023-06-20
CN116159024A (zh) 2023-05-26
HRP20221185T1 (hr) 2022-12-09
KR102511284B1 (ko) 2023-03-16
US11235023B2 (en) 2022-02-01
SG10202113280XA (en) 2021-12-30
IL263112B2 (en) 2023-10-01
BR112018074532B1 (pt) 2022-02-08
AU2017273507A1 (en) 2018-12-13
IL263114A (en) 2018-12-31
AU2017273508A1 (en) 2018-12-13
EA039603B1 (ru) 2022-02-16
ZA201807772B (en) 2022-10-26
US20200230203A1 (en) 2020-07-23
MA45167A (fr) 2019-04-10
SG11201810137UA (en) 2018-12-28
CA3024522A1 (fr) 2017-12-07
HUE060119T2 (hu) 2023-02-28
JP2019523222A (ja) 2019-08-22
HRP20221194T1 (hr) 2022-12-09
JP7286319B2 (ja) 2023-06-05
BR112018074551A2 (pt) 2019-03-06
EP3463281A1 (fr) 2019-04-10
PT3463280T (pt) 2022-10-07
CN109310613A (zh) 2019-02-05
JP2019523763A (ja) 2019-08-29
CL2018003391A1 (es) 2019-05-03
RS63639B1 (sr) 2022-10-31
ES2928050T3 (es) 2022-11-15
RS63622B1 (sr) 2022-10-31
CA3024522C (fr) 2024-06-25
CN109195580A (zh) 2019-01-11
ZA201807773B (en) 2022-07-27
KR20190015309A (ko) 2019-02-13
US11844823B2 (en) 2023-12-19
MX2018014752A (es) 2019-04-25
KR20190011750A (ko) 2019-02-07
WO2017207118A1 (fr) 2017-12-07
IL263112A (en) 2018-12-31
CA3024521A1 (fr) 2017-12-07
ES2927948T3 (es) 2022-11-14
SMT202200404T1 (it) 2022-11-18

Similar Documents

Publication Publication Date Title
PL3505535T3 (pl) Przeciwciało monoklonalne anty-pd1, jego kompozycja farmaceutyczna i jego zastosowanie
EP3362060A4 (fr) Biomarqueurs associés au diabète et de traitement d'affections associées au diabète
MA45167A (fr) Peptidomimétique en épingle à cheveux bêta présentant une activité d'inhibition de l'élastase et formes pharmaceutiques aérosols correspondantes
EP4043463C0 (fr) Dérivé à cycle condensé ayant une activité inhibitrice de mgat2
BRPI0815578A2 (pt) Peptídeo de cdca1 e agente farmacêutico compreendendo o mesmo.
BR112017028486A2 (pt) instrumento para higiene bucal e cerdas de monofilamento para uso com o mesmo
EP3399033A4 (fr) Marqueur peptidique et protéine marquée comprenant celui-ci
EP3318265A4 (fr) Peptide à activité antivirale et composition comprenant ce dernier
PL3636774T3 (pl) Sposób wykrywania chorób wywołanych C. perfringens u zwierząt
HUE052837T2 (hu) Lizoszóma-tárolási betegségre irányuló gyógyászati készítmények és alkalmazásaik
EP3452040A4 (fr) Formulations et traitements ayant recours à des hydroxypyridonates décorporants d'actinide/lanthanide
EP3444263A4 (fr) Peptide présentant une activité anti-inflammatoire et utilisation correspondante
IL279877A (en) Ivosidenib forms and pharmaceutical compositions
EP3520651A4 (fr) Poils de brosse à dents en polycétone, et brosse à dents les comprenant
EP3539978A4 (fr) Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif
IL283619A (en) Compounds with pde9a prophylactic activity, and their medicinal use
EP3449524A4 (fr) Électrolyte comprenant des dinitriles et des fluoroéthers cycliques
ITUA20161610A1 (it) Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
MA52869A (fr) Peptides ayant une activité inhibitrice sur l'exocytose neuronale
EP3534967A4 (fr) Dosage d'activité de protéine d'escorte de rab
HRP20190381T1 (hr) Herbicidni pripravci koji sadrže izoksaflutol i diflufenikan kao jedine herbicidno aktivne sastojke
IL283620A (en) Compounds with pde9a prophylactic activity, and their medicinal uses
EP3315128A4 (fr) Régime de dosage d'agent thérapeutique contre l'ataxie associée à la dégénérescence spino-cérébelleuse
Griffis Corea, without and within
杨春芝 On The Translation of Chinese Culture-loaded Words in Chinese American Literature